Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Change in Account Payables (2015 - 2020)

Alterity Therapeutics' quarterly Change in Account Payables came in at -$425086.2 in Q2 2020, down 191.54% year-on-year from $464361.3 in Q3 2019, and down 108.38% quarter-over-quarter from $5.1 million in Q4 2019.

Alterity Therapeutics has reported Change in Account Payables for 6 years, with the latest figure at -$425086.2 in Q2 2020.

  • For the quarter ending Q2 2020, Change in Account Payables fell 191.54% year-over-year to -$425086.2; the trailing twelve-month figure through Jun 2020 stood at $4.7 million (up 247.47% YoY), and the FY2025 full-year result was -$1.3 million, down 280.25% from the prior year.
  • Change in Account Payables for Q2 2020 stood at -$425086.2, down from $5.1 million in the prior quarter.
  • The five-year high for Change in Account Payables was $5.1 million in Q4 2019, with the low at -$3.2 million in Q4 2017.
  • Average Change in Account Payables over 5 years is $26466.9, with a median of -$301256.3 recorded in 2016.
  • Year-over-year, Change in Account Payables plunged 1065.61% in 2017 and jumped 5175.08% in 2019.
  • Tracing ATHE's Change in Account Payables over 5 years: stood at -$278480.6 in 2016, then sank by 1065.61% to -$3.2 million in 2017, then soared by 87.27% to -$413122.1 in 2018, then soared by 1327.75% to $5.1 million in 2019, then tumbled by 108.38% to -$425086.2 in 2020.
  • The last three Change in Account Payables figures came in at -$425086.2 (Q2 2020), $5.1 million (Q4 2019), and $464361.3 (Q2 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -3.26 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 35.60 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - 16.86 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 -425,086.16
Jun 30, 2020 -425,086.16
Dec 31, 2019 5.07 Mn
Dec 31, 2019 5.07 Mn
Jun 30, 2019 464,361.28
Jun 30, 2019 464,361.28
Dec 31, 2018 -413,122.12
Dec 31, 2018 -413,122.12
Jun 30, 2018 8,802.92
Jun 30, 2018 8,802.92
Dec 31, 2017 -3.25 Mn
Dec 31, 2017 -3.25 Mn
Jun 30, 2017 -643,134.45
Jun 30, 2017 -643,134.45
Dec 31, 2016 -278,480.55
Dec 31, 2016 -278,480.55
Jun 30, 2016 -301,256.34
Jun 30, 2016 -301,256.34
Dec 31, 2015 -5.13 Mn
Dec 31, 2015 -5.13 Mn